Results 61 to 70 of about 645,171 (161)

Biochemical Characterization of a Kunitz-Type Protease Inhibitor From Mimosa regnellii and Its Effects on Melanoma Cell Viability and Angiogenesis. [PDF]

Chem Biodivers
Rabêlo LMA, Cardoso PHO, Nobre LTDB, Dos Santos PIM, Lucena SV, Serquiz RP, Bemquerer MP, Rocha HAO, Nader HB, Dos Santos EA, de Oliveira AS, Frihling BEF, Migliolo L.   +12 more
europepmc   +1 more source

Structure-based pharmacophore modeling, high-throughput screening, and molecular dynamics identify a novel DrugBank-derived HIV-1 protease inhibitor. [PDF]

PLoS One
Khazaal Nazal AS, Rashid Alrashedi AM, Risan Al-Iessa LA, Ali Rabeea MAH.   +3 more
europepmc   +1 more source

Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease Inhibitor. [PDF]

J Med Chem
Papillon JPN, Yuan J, Hesse MJ, Zhang L, Robinson RI, Ware NF, Hornak V, Karki RG, Kirrane T, Garland K, Joseph S, Moquin SA, Lakshminarayana SB, Tandeske L, Dovala D, Knapp M, Ornelas E, Fuller D, Ho PI, Xie X, Vulic K, Skolnik SM, Gao J, Zambrowski M, Spiess M, Duca JS, Busby SA, Schirle M, Robinson M, Shi PY, Moser HE, Sarko C, Bradner JE, Diagana TT, Tallarico JA.   +34 more
europepmc   +1 more source

Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects. [PDF]

Antimicrob Agents Chemother
Li X, Li B, Wang M, Wang J, Lu J, Mao J, Zhang T, Tang Y, Yan W, Li C, Zhang G, Ding Y.   +11 more
europepmc   +1 more source

Longitudinal Analysis of HIV-2 Proviral DNA Reveals Archived Protease Inhibitor Resistance and Reservoir Evolution over Eight Years. [PDF]

Int J Mol Sci
Gonçalves P, Lopes I, Martins A, Maia F, Martin F, Borrego P, Antunes F, Valadas E, Palladino C, Bártolo I, Taveira N.   +10 more
europepmc   +1 more source

Sequential Optimization Approach Toward an Azapeptide-Based SARS-CoV-2 Main Protease Inhibitor. [PDF]

Arch Pharm (Weinheim)
Voget R, Steiger V, Breidenbach J, Sylvester K, Müller-Ruttloff C, Yang CC, Ziebuhr J, Sträter N, Müller CE, Gütschow M.   +9 more
europepmc   +1 more source

YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice. [PDF]

Nat Commun
Nan J, Shuai H, Qiao J, Zeng R, Du L, Chen Y, Yoon C, Hu J, Guo W, Wang L, Huang C, Zhu L, Li Y, Zhang S, Deng X, Sun J, Du L, Ma R, Huang Q, Lei J, Chu H, Yang S.   +21 more
europepmc   +1 more source

Downregulation of the Transglutaminase 2-NF-κB Inflammatory Axis by a Fusion Protein of Cementoin and Secretory Leukocyte Protease Inhibitor Reduces Corneal Angiogenesis. [PDF]

Int J Mol Sci
Salica JP, Potilinski MC, Ortiz G, Maffia PC, Guerrieri D, Chuluyan E, Gallo JE.   +6 more
europepmc   +1 more source

Secretory leukocyte protease inhibitor (SLPI) promotes cholangiocarcinoma progression via inflammation-associated and vasculogenic mechanisms. [PDF]

PLoS One
Chueajedton K, Chueaiphuk C, Inpad J, Kumphune S, Kaewkong W, Surangkul D, Sawanyawisuth K, Cha'on U, Phimsen S.   +8 more
europepmc   +1 more source

Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophages. [PDF]

Sci Rep
Jarisarapurin W, Kunchana K, Srisopar O, Bunsoong K, Roytrakul S, Kumphune S.   +5 more
europepmc   +1 more source